- Home
- HBB vs VYGR Comparison
HBB vs VYGR Comparison
Compare HBB & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBB
- VYGR
- Stock Information
- Founded
- HBB 1904
- VYGR 2013
- Country
- HBB United States
- VYGR United States
- Employees
- HBB N/A
- VYGR N/A
- Industry
- HBB Home Furnishings
- VYGR Biotechnology: Pharmaceutical Preparations
- Sector
- HBB Consumer Discretionary
- VYGR Health Care
- Exchange
- HBB Nasdaq
- VYGR Nasdaq
- Market Cap
- HBB 292.6M
- VYGR 309.7M
- IPO Year
- HBB 2017
- VYGR 2015
- Fundamental
- Price
- HBB $20.04
- VYGR $6.57
- Analyst Decision
- HBB
- VYGR Strong Buy
- Analyst Count
- HBB 0
- VYGR 9
- Target Price
- HBB N/A
- VYGR $16.44
- AVG Volume (30 Days)
- HBB 56.5K
- VYGR 584.2K
- Earning Date
- HBB 10-30-2024
- VYGR 11-12-2024
- Dividend Yield
- HBB 2.29%
- VYGR N/A
- EPS Growth
- HBB 107.04
- VYGR N/A
- EPS
- HBB 1.88
- VYGR 0.47
- Revenue
- HBB $647,834,000.00
- VYGR $163,784,000.00
- Revenue This Year
- HBB $4.60
- VYGR N/A
- Revenue Next Year
- HBB N/A
- VYGR N/A
- P/E Ratio
- HBB $10.53
- VYGR $14.09
- Revenue Growth
- HBB 5.30
- VYGR 3.40
- 52 Week Low
- HBB $14.34
- VYGR $5.19
- 52 Week High
- HBB $31.78
- VYGR $11.72
- Technical
- Relative Strength Index (RSI)
- HBB 35.28
- VYGR 53.48
- Support Level
- HBB $18.54
- VYGR $5.54
- Resistance Level
- HBB $20.11
- VYGR $7.44
- Average True Range (ATR)
- HBB 0.91
- VYGR 0.42
- MACD
- HBB 0.30
- VYGR 0.12
- Stochastic Oscillator
- HBB 51.19
- VYGR 61.33
About HBB Hamilton Beach Brands Holding Company
Hamilton Beach Brands Holding Co, through its subsidiaries, is engaged in consumer, commercial, and specialty small appliances and specialty retail. It designs, markets, and distributes small branded electric household and specialty housewares small appliances, as well as commercial products for restaurants, bars, and hotels.
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.